B+
Bull case
25%
Probability
Target price
$11.00
+52.1% vs current
IBRX
ImmunityBioANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$7.50
+3.7% vs current
B-
Bear case
25%
Probability
Target price
$4.50
-37.8% vs current
AI sentiment snapshot
Latest data as of 2026-04-17
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+54.4
Score
AI commentary
The setup has improved from a pure survival story into a monitored commercial execution story, but it is still not clean enough for a high-conviction bullish call. Primary-source evidence supports real revenue momentum and added liquidity, yet the financing structure, ongoing balance-sheet pressure, and need for formal 10-Q confirmation keep the thesis in cautious watch mode.
RankAlpha Sentiment Codex - 2026-04-17
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-15eventQ1 2026 10-Q needs to reconcile preliminary revenue and liquidity figuresHigh impact
The April 9, 2026 8-K furnished preliminary Q1 2026 net product revenue of about $44.2 million and cash, cash equivalents, and marketable securities of about $380.9 million, with explicit warning that final 10-Q figures may differ; the formal Q1 filing is the next hard checkpoint for revenue quality, cash use, and any updated outlook [#8-K-2026-04-09].
2026-05-15eventMarch financing amendment improves cash but raises the revenue-interest burdenHigh impact
The March 30, 2026 8-K says ImmunityBio received $75.0 million gross under a second amendment to its Revenue Interest Purchase Agreement, but the purchaser revenue share stepped up to a tiered 5.625% to 12.50% of covered-territory net sales from 4.5% to 10.0%; investors still need cleaner disclosure on the net runway benefit versus the added claim on future ANKTIVA sales [#8-K-2026-03-30].
2026-12-31catalystANKTIVA commercial adoption and bladder-cancer label expansion remain the core upsideHigh impact
Primary company materials point to continued ANKTIVA commercialization momentum: the April 9 exhibit cited 168% year-over-year Q1 unit growth, March 2026 NCCN guideline inclusion for papillary-only disease, and five approved or authorized regulatory jurisdictions, while the 10-K showed about $113 million of 2025 net product revenue; if these trends persist and the fully enrolled QUILT-2.005 program stays on track for a 2026 supplemental BLA, the equity can re-rate, but proof still depends on repeatable execution and regulatory follow-through [#8-K-2026-04-09] [#10-K-2026-02-23].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-17 • Updated nightlySource: Internal modelMethodology